普生(4117) 公告董事會決議與子公司Pacgen公司簽訂蛋白質藥P-113授權案 發言時間 102/04/1118:42:05發言人 林孟慧 發言人職稱 行銷部資深經理 發言人電話 (03)5779221 主旨 : 公告董事會決議與子公司Pacgen公司簽訂蛋白質藥P-113授權案符合條款第41款事實發生日102/04/11說明 1.事實發生日:102/04/112.公司名稱:普生股份有限公司3.與公司關係(請輸入本公司或聯屬公司):本公司4.相互持股比例(若前項為本公司，請填不適用):不適用5.發生緣由:為因應未來診斷與藥物開發整合趨勢。6.因應措施:無7.其他應敘明事項:無以上資料均由各公司依發言當時所屬市場別之規定申報後，由本系統對外公佈，資料如有虛偽不實，均由該公司負責.
Pacgen Expands PAC-113 License VANCOUVER, BRITISH COLUMBIA--(Marketwire - Jan. 30, 2012) - Pacgen Biopharmaceuticals Corporation ("Pacgen" or the "Company") (TSX VENTURE:PGA) announced today that the Company has signed an amendment to its license agreement with Demegen, Inc., to expand its exclusive worldwide rights and license to PAC-113 for additional indications, including vaginal, dermatological and ophthalmic applications. There was no payment associated with the amendment license agreement. All other terms of the license agreement remained unchanged. Pacgen has right to sublicense all these additional indications as well as oral indications covered in its original license. Dr. Ming S. Liu, Chief Executive Officer of Pacgen reports: "We are currently focused on strengthening our technology portfolio and have undertaken a number of business initiatives, with the expanded PAC-113 license being one of them. Antimicrobial peptides are known to have potent broad-spectrum antimicrobial activities against a wide range of microorganisms including bacteria, protozoa, fungi, and yeast. We believe PAC-113 has potential for a number of important hygienic and medical uses. The extensive safety data package together with the expanded PAC-113 license rights will allow Pacgen to pursue broader business opportunity." PAC-113 is a 12 amino-acid antimicrobial peptide derived from a naturally occurring histatin protein found in human saliva. This peptide alters the permeability of fungal cell membranes causing cell death. In June 2008, Pacgen announced positive results from its Phase IIb clinical trial demonstrating that PAC-113 is effective in the treatment of oral Candidiasis and compares favorably to the efficacy demonstrated by Nystatin, a current standard of care.
About Pacgen Pacgen is a life science technology company focused on the commercialization of biomedical products and services, including its previous development of novel therapeutic drug candidates. The Company is currently looking to facilitate its corporate transformation from a bio-pharma R&D business into a revenue-generating company. For additional information, please visit www.pacgenbiopharm.com.
About PAC-113 PAC-113 is a 12 amino-acid antimicrobial peptide derived from a naturally occurring histatin protein found in saliva. This peptide alters the permeability of fungal cell membranes causing cell death. In addition, PAC-113 also interacts with fungal mitochondria causing production of reactive oxygen species that lead to fungal cell destruction. This activity is unique to histatin proteins. Current treatments for Candida infections are not effective in eliminating the infection, can have serious side effects, have significant potential for drug interaction, and/or do not prevent the development of drug-resistant fungal infection. PAC-113 is easily administered and well-tolerated by patients as it is formulated as a sugar-free, pleasant tasting, non-viscous mouthrinse with a neutral pH. It also has a prolonged half-life in the saliva giving it the potential to extend the duration of the therapeutic effect, increasing the cure rate and reducing the time to relapse.
No comments:
Post a Comment